115 related articles for article (PubMed ID: 1879086)
1. The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis--a preliminary study.
Lau CS; McLaren M; Saniabadi A; Scott N; Belch JJ
Clin Exp Rheumatol; 1991; 9(3):271-3. PubMed ID: 1879086
[TBL] [Abstract][Full Text] [Related]
2. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis.
Lau CS; Belch JJ; Madhok R; Cappell H; Herrick A; Jayson M; Thompson JM
Clin Exp Rheumatol; 1993; 11(1):35-40. PubMed ID: 8453795
[TBL] [Abstract][Full Text] [Related]
3. Cicaprost, an orally active prostacyclin analogue: its effects on platelet aggregation and skin blood flow in normal volunteers.
Belch JJ; McLaren M; Lau CS; Mackay IR; Bancroft A; McEwen J; Thompson JM
Br J Clin Pharmacol; 1993 Jun; 35(6):643-7. PubMed ID: 8329292
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of beraprost sodium on Raynaud's phenomenon in patients with systemic sclerosis].
Kaburaki J; Kuwana M; Akizuki M; Takano M; Tojo T
Nihon Rinsho Meneki Gakkai Kaishi; 1995 Feb; 18(1):29-35. PubMed ID: 7553036
[TBL] [Abstract][Full Text] [Related]
5. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.
McHugh NJ; Csuka M; Watson H; Belcher G; Amadi A; Ring EF; Black CM; Maddison PJ
Ann Rheum Dis; 1988 Jan; 47(1):43-7. PubMed ID: 2449871
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of Raynaud's phenomenon in scleroderma with a new stable prostacyclin derivative].
Keller J; Kaltenecker A; Schricker KT; Krais T; Schönberger A; Gevatter M; Hornstein OP
Dtsch Med Wochenschr; 1984 Sep; 109(38):1433-8. PubMed ID: 6383760
[TBL] [Abstract][Full Text] [Related]
7. Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis.
Balbir-Gurman A; Braun-Moscovici Y; Livshitz V; Schapira D; Markovits D; Rozin A; Boikaner T; Nahir AM
Clin Rheumatol; 2007 Sep; 26(9):1517-21. PubMed ID: 17401513
[TBL] [Abstract][Full Text] [Related]
8. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.
Belch JJ; Newman P; Drury JK; McKenzie F; Capell H; Leiberman P; Forbes CD; Prentice CR
Lancet; 1983 Feb; 1(8320):313-5. PubMed ID: 6130329
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of cicaprost in healthy volunteers after oral administration of 5 to 20 micrograms.
Hildebrand M; Staks T; Nieuweboer B
Eur J Clin Pharmacol; 1990; 39(2):149-53. PubMed ID: 2253664
[TBL] [Abstract][Full Text] [Related]
10. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].
Correa MJ; Mariz HA; Andrade LE; Kayser C
Rev Bras Reumatol; 2014; 54(6):452-8. PubMed ID: 25458027
[TBL] [Abstract][Full Text] [Related]
11. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.
Mavrikakis ME; Lekakis JP; Papamichael CM; Stamatelopoulos KS; Kostopoulos ChC; Stamatelopoulos SF
Int J Vitam Nutr Res; 2003 Feb; 73(1):3-7. PubMed ID: 12690904
[TBL] [Abstract][Full Text] [Related]
12. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue.
Yardumian DA; Isenberg DA; Rustin M; Belcher G; Snaith ML; Dowd PM; Machin SJ
Br J Rheumatol; 1988 Jun; 27(3):220-6. PubMed ID: 2454140
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers.
Demolis JL; Robert A; Mouren M; Funck-Brentano C; Jaillon P
J Cardiovasc Pharmacol; 1993 Nov; 22(5):711-6. PubMed ID: 7506323
[TBL] [Abstract][Full Text] [Related]
15. Double-blind, placebo-controlled study of intravenous prostacyclin on hemodynamics in severe Raynaud's phenomenon: the acute vasodilatory effect is not sustained.
Kingma K; Wollersheim H; Thien T
J Cardiovasc Pharmacol; 1995 Sep; 26(3):388-93. PubMed ID: 8583779
[TBL] [Abstract][Full Text] [Related]
16. Platelet sensitivity to a prostacyclin analogue in systemic sclerosis.
Belch JJ; O'Dowd A; Forbes CD; Sturrock RD
Br J Rheumatol; 1985 Nov; 24(4):346-50. PubMed ID: 2415199
[TBL] [Abstract][Full Text] [Related]
17. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
18. Oral cicaprost reduces platelet and neutrophil activation in experimental hypercholesterolemia.
Hohlfeld T; Weber A; Schrör K
Agents Actions Suppl; 1992; 37():289-96. PubMed ID: 1632303
[TBL] [Abstract][Full Text] [Related]
19. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Serri J; Legré R; Veit V; Guardia C; Gay AM
Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
[TBL] [Abstract][Full Text] [Related]
20. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.
Schiopu E; Hsu VM; Impens AJ; Rothman JA; McCloskey DA; Wilson JE; Phillips K; Seibold JR
J Rheumatol; 2009 Oct; 36(10):2264-8. PubMed ID: 19755613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
